Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 27-Dec-23 9:00 AM View:  | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 22-Dec-23 | Purchase | 25,000 | $1.40 | $35,000.00 | 28% 88.75K to 113.75K | |
| 19-Dec-23 4:15 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 18-Dec-23 | Purchase | 10,000 | $1.84 | $18,442.00 | 13% 78.75K to 88.75K | |
| 04-Dec-23 5:00 PM View: | Puttagunta Sailaja Chief Medical Officer | Iterum Therapeutics Plc (ITRM) | 01-Dec-23 | Grant | 8,333 | -- | -- | 168% 4.97K to 13.3K | |
| 04-Dec-23 5:00 PM View: | Puttagunta Sailaja Chief Medical Officer | Iterum Therapeutics Plc (ITRM) | 01-Dec-23 | Payment of Exercise | 2,933 | $2.12 | $6,217.96 | (22%) 13.3K to 10.37K | |
| 27-Nov-23 5:00 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 22-Nov-23 | Purchase | 20,000 | $2.03 | $40,690.00 | 34% 58.75K to 78.75K | |
| 20-Nov-23 5:00 PM View: | Fishman Corey N. Chief Executive Officer Director | Iterum Therapeutics Plc (ITRM) | 20-Nov-23 | Purchase | 10,000 | $1.59 | $15,863.00 | 22% 44.45K to 54.45K | |
| 02-Oct-23 9:22 AM View: | Hunt Ronald Director | Iterum Therapeutics Plc (ITRM) | 01-Oct-23 | Option Exercise | 5,479 | -- | -- | 5% 105.95K to 111.43K | |
| 02-Oct-23 9:20 AM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 01-Oct-23 | Option Exercise | 3,487 | -- | -- | 6% 55.27K to 58.75K | |
| 03-Jul-23 8:00 AM View: | Hunt Ronald Director | Iterum Therapeutics Plc (ITRM) | 01-Jul-23 | Option Exercise | 2,796 | -- | -- | 3% 103.16K to 105.95K | |
| 03-Jul-23 8:00 AM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 01-Jul-23 | Option Exercise | 1,779 | -- | -- | 3% 53.49K to 55.27K | |
| 15-Jun-23 5:00 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 15-Jun-23 | Option Exercise | 15,853 | -- | -- | 42% 37.63K to 53.49K | |
| 15-Jun-23 5:00 PM View: | Chin Mark Director | Iterum Therapeutics Plc (ITRM) | 15-Jun-23 | Option Exercise | 15,853 | -- | -- | 646% 2.45K to 18.31K | |
| 15-Jun-23 5:00 PM View: | Hecht Beth Director | Iterum Therapeutics Plc (ITRM) | 15-Jun-23 | Option Exercise | 15,853 | -- | -- | 531% 2.99K to 18.84K | |
| 03-Apr-23 8:00 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 01-Apr-23 | Option Exercise | 1,299 | -- | -- | 4% 36.34K to 37.64K | |
| 03-Apr-23 8:00 PM View: | Hunt Ronald Director | Iterum Therapeutics Plc (ITRM) | 01-Apr-23 | Option Exercise | 2,041 | -- | -- | 51% 4.03K to 6.07K | |
| 14-Mar-23 6:00 PM View: | Fishman Corey N. Chief Executive Officer Director | Iterum Therapeutics Plc (ITRM) | 11-Mar-23 | Payment of Exercise | 5,683 | $0.96 | $5,455.68 | (11%) 50.13K to 44.45K | |
| 14-Mar-23 6:00 PM View: | Matthews Judith M. Chief Financial Officer | Iterum Therapeutics Plc (ITRM) | 11-Mar-23 | Grant | 6,666 | -- | -- | 153% 4.35K to 11.02K | |
| 14-Mar-23 6:00 PM View: | Fishman Corey N. Chief Executive Officer Director | Iterum Therapeutics Plc (ITRM) | 11-Mar-23 | Grant | 14,333 | -- | -- | 40% 35.8K to 50.13K | |
| 14-Mar-23 6:00 PM View: | Matthews Judith M. Chief Financial Officer | Iterum Therapeutics Plc (ITRM) | 11-Mar-23 | Payment of Exercise | 2,883 | $0.96 | $2,767.68 | (26%) 11.02K to 8.13K | |
| 04-Jan-23 6:00 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 01-Jan-23 | Option Exercise | 761 | -- | -- | 2% 35.58K to 36.34K | |
| 04-Jan-23 6:00 PM View: | Hunt Ronald Director | Iterum Therapeutics Plc (ITRM) | 01-Jan-23 | Option Exercise | 1,197 | -- | -- | 1% 99.92K to 101.12K | |
| 05-Dec-22 5:00 PM View: | Puttagunta Sailaja Chief Medical Officer | Iterum Therapeutics Plc (ITRM) | 02-Dec-22 | Sale | 3,365 | $1.32 | $4,441.80 | (40%) 8.33K to 4.97K | |
| 05-Dec-22 5:00 PM View: | Puttagunta Sailaja Chief Medical Officer | Iterum Therapeutics Plc (ITRM) | 01-Dec-22 | Grant | 8,334 | -- | -- | 100% 0 to 8.33K | |
| 20-Sep-22 6:00 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 20-Sep-22 | Sale | 7,246 | $1.78 | $12,910.20 | (95%) 7.66K to 0.41K | |
| 20-Sep-22 6:00 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 19-Sep-22 | Sale | 15,000 | $1.77 | $26,478.00 | (66%) 22.66K to 7.66K | |
| 20-Sep-22 6:00 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 16-Sep-22 | Private Sale | 15,000 | $1.90 | $28,542.00 | (40%) 37.66K to 22.66K | |
| 15-Sep-22 5:36 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 15-Sep-22 | Sale | 15,000 | $2.02 | $30,271.50 | (28%) 52.66K to 37.66K | |
| 15-Sep-22 5:36 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 14-Sep-22 | Sale | 15,000 | $2.10 | $31,456.50 | (22%) 67.66K to 52.66K | |
| 15-Sep-22 5:36 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 13-Sep-22 | Private Sale | 15,000 | $2.14 | $32,118.00 | (18%) 82.66K to 67.66K | |
| 12-Sep-22 9:01 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 12-Sep-22 | Sale | 15,000 | $2.31 | $34,608.00 | (15%) 97.66K to 82.66K | |
| 12-Sep-22 9:01 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 09-Sep-22 | Sale | 15,000 | $2.32 | $34,729.50 | (13%) 112.66K to 97.66K | |
| 12-Sep-22 9:01 PM View: | Ahrens Brenton Karl Director | Iterum Therapeutics Plc (ITRM) | 08-Sep-22 | Private Sale | 3,298 | $2.26 | $7,465.02 | (3%) 115.95K to 112.66K | |
| 09-Sep-22 6:00 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 07-Sep-22 | Purchase | 10,000 | $2.22 | $22,200.00 | 39% 25.58K to 35.58K | |
| 24-Jun-22 6:00 PM View: | Hunt Ronald Director | Iterum Therapeutics Plc (ITRM) | 23-Jun-22 | Option Exercise | 36,798 | -- | -- | 3% 1.46M to 1.5M | |
| 24-Jun-22 6:00 PM View: | Chin Mark Director | Iterum Therapeutics Plc (ITRM) | 23-Jun-22 | Option Exercise | 36,798 | -- | -- | 100% 0 to 36.8K | |
| 24-Jun-22 6:00 PM View: | Hecht Beth Director | Iterum Therapeutics Plc (ITRM) | 23-Jun-22 | Option Exercise | 36,798 | -- | -- | 460% 8.01K to 44.8K | |
| 24-Jun-22 6:00 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 23-Jun-22 | Option Exercise | 36,798 | -- | -- | 11% 346.85K to 383.65K | |
| 29-Mar-22 8:00 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 25-Mar-22 | Option Exercise | 10,494 | -- | -- | 3% 336.36K to 346.85K | |
| 22-Mar-22 7:00 PM View: | Hecht Beth Director | Iterum Therapeutics Plc (ITRM) | 18-Mar-22 | Option Exercise | 7,642 | -- | -- | 2094% 0.36K to 8.01K | |
| 15-Mar-22 5:01 PM View: | Matthews Judith M. Chief Financial Officer | Iterum Therapeutics Plc (ITRM) | 14-Mar-22 | Sale | 47,132 | $0.38 | $17,910.20 | (37%) 128.63K to 81.5K | |
| 15-Mar-22 5:00 PM View: | Fishman Corey N. Chief Executive Officer Director | Iterum Therapeutics Plc (ITRM) | 11-Mar-22 | Option Exercise | 215,000 | -- | -- | 67% 322.01K to 537.01K | |
| 15-Mar-22 5:01 PM View: | Matthews Judith M. Chief Financial Officer | Iterum Therapeutics Plc (ITRM) | 11-Mar-22 | Grant | 100,000 | -- | -- | 349% 28.63K to 128.63K | |
| 27-Jul-21 9:30 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 25-Jul-21 | Grant | 80,000 | -- | -- | 31% 256.36K to 336.36K | |
| 12-Feb-21 8:22 PM View: | Denner Alexander J 10% Owner | Iterum Therapeutics Plc (ITRM) | 12-Feb-21 | Market Sale | 10,619,900 | $2.27 | $24,107,300.00 | (25%) 41.86M to 31.24M | |
| 12-Feb-21 8:22 PM View: | Denner Alexander J 10% Owner | Iterum Therapeutics Plc (ITRM) | 11-Feb-21 | Conversion | 20,619,900 | -- | -- | 66% 31.24M to 51.86M | |
| 12-Feb-21 8:22 PM View: | Denner Alexander J 10% Owner | Iterum Therapeutics Plc (ITRM) | 11-Feb-21 | Market Sale | 10,000,000 | $2.59 | $25,900,000.00 | (19%) 51.86M to 41.86M | |
| 08-Feb-21 5:22 PM View: | Ra Capital Management, LLC 10% Owner | Iterum Therapeutics Plc (ITRM) | 04-Feb-21 | Conversion | 11,651,600 | -- | -- | 100% 0 to 11.65M | |
| 27-Jan-21 7:32 PM View: | Dunne Michael W. Director | Iterum Therapeutics Plc (ITRM) | 26-Jan-21 | Market Sale | 33,143 | $1.73 | $57,337.40 | (11%) 289.5K to 256.36K | 18% |
| 27-Jan-21 7:35 PM View: | Fishman Corey N. President & CEO Director | Iterum Therapeutics Plc (ITRM) | 26-Jan-21 | Market Sale | 85,445 | $1.73 | $147,820.00 | (21%) 407.45K to 322.01K | 18% |
| 27-Jan-21 7:32 PM View: | Matthews Judith M. Chief Financial Officer | Iterum Therapeutics Plc (ITRM) | 26-Jan-21 | Market Sale | 33,868 | $1.73 | $58,591.60 | (54%) 62.5K to 28.63K | 18% |
